AstraZeneca PLC (LON:AZN - Get Free Report)'s stock price passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of £139.13 and traded as high as £151.08. AstraZeneca shares last traded at £149.89, with a volume of 1,200,218 shares traded.
Analyst Upgrades and Downgrades
A number of equities research analysts recently commented on AZN shares. Berenberg Bank boosted their target price on AstraZeneca from £145 to £160 and gave the stock a "buy" rating in a research report on Tuesday, January 27th. JPMorgan Chase & Co. restated an "overweight" rating on shares of AstraZeneca in a research report on Thursday, January 15th. Citigroup upped their price objective on AstraZeneca from £170 to £180 and gave the company a "buy" rating in a research report on Friday, April 10th. Deutsche Bank Aktiengesellschaft upped their price objective on AstraZeneca from £105 to £110 and gave the company a "sell" rating in a research report on Thursday, January 15th. Finally, Shore Capital Group restated a "buy" rating on shares of AstraZeneca in a research report on Friday, January 16th. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, AstraZeneca presently has an average rating of "Moderate Buy" and a consensus target price of £152.50.
View Our Latest Research Report on AstraZeneca
AstraZeneca Stock Performance
The company has a debt-to-equity ratio of 60.87, a current ratio of 0.94 and a quick ratio of 0.59. The business has a 50-day simple moving average of £148.16 and a 200-day simple moving average of £139.13. The firm has a market capitalization of £229.18 billion, a PE ratio of 22.60, a P/E/G ratio of 0.86 and a beta of 0.28.
About AstraZeneca
(
Get Free Report)
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
